Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-101 in Healthy Volunteers and Ulcerative Colitis
NCT04224857Phase 1Completed
- Sponsor
- Applied Molecular Transport
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing AMT-101 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-emergent adverse events at 14 days. Started Apr 2019; status: completed.
02
Drugs
AMT-101
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04224857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224857.